Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol

2005/07/15 by P. D. Home, SJ Pocock, S. J. Pocock +14 · 14 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Peroxisome Proliferator-Activated Receptors #Diabetes, Cardiovascular Risks, and Lipoproteins #Diabetes Treatment and Management

paper · pdf · doi:10.1007/s00125-005-1869-1

Citations

• Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Cited by

• Type 2 diabetes subtypes for precision medicine: methodological challenges and alternative prediction-based approaches
• Rosiglitazone for type 2 diabetes mellitus. [europepmc]
• Should We Use PPAR Agonists to Reduce Cardiovascular Risk? [europepmc]
• Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). [europepmc]
• Reassessing the cardiovascular risks and benefits of thiazolidinediones. [europepmc]
• Early vascular aging (EVA): consequences and prevention. [europepmc]
• Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. [europepmc]
• Rosiglitazone is associated with mortality in chronic hemodialysis patients. [europepmc]
• Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. [europepmc]
• Thiazolidinedione treatment and constitutive-PPARgamma activation induces ectopic adipogenesis and promotes age-related thymic involution. [europepmc]
• Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters. [europepmc]
• How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid? [europepmc]
• Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. [europepmc]
• Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. [europepmc]